da Silva Morais Alain, Saliez Alain, Leclercq Isabelle, Horsmans Yves, Stärkel Peter
Department of Gastroenterology, Catholic University of Louvain, St Luc University Hospital, 1200 Brussels, Belgium.
Clin Sci (Lond). 2008 Jan;114(1):73-83. doi: 10.1042/CS20070152.
Ras oncoproteins are probably implicated in normal and malignant cell growth in various organs. Inhibition of Ras interferes with cell proliferation of non-hepatic cells in vitro and in vivo. A potential role for Ras in normal and malignant hepatocyte proliferation prompted us to evaluate the impact of Ras inhibition by FTS (S-farnesylthiosalicylic acid) on hepatocyte proliferation in vitro in the human hepatic tumour cell line HepG2 and in vivo after PH (partial hepatectomy) in rats. Rats were administered with FTS intraperitoneally (1, 8 and 16 h after PH) and killed 12, 24 and 48 h after PH. Cell proliferation, phosphorlyation of members of the MAPK (mitogen-activated protein kinase) pathway and levels and activity of cell cycle effectors (cyclin D, cyclin E, Cdk2 and Cdk4) were assessed in FTS-treated rats compared with controls. FTS significantly decreased overall cell count, PCNA (proliferating-cell nuclear antigen) expression and BrdU (bromodeoxyuridine) incorporation into HepG2 cells after 7 days of culture. FTS treatment significantly reduced BrdU incorporation and PCNA expression in hepatocytes after PH. Unlike control rats, cell-membrane expression of Ras was decreased in FTS-treated animals after PH, resulting in decreased Raf membrane recruitment and phosphorylation and in reduced phosphorylation of ERK1/2 (extracellular-signal-regulated kinase 1/2). The antiproliferative effect of FTS was linked to a decrease in expression and activity of the cyclin E/Cdk2 complex, without affecting cyclin D and Cdk4. Ras inhibition by FTS significantly decreased proliferation of HepG2 cells and normal hepatocytes after a strong and highly synchronized proliferation stimulus elicited by PH. The inhibitory effect was at least partially mediated by inhibition of Ras/Raf/MAPK signalling. It appears worthwhile to evaluate the impact of Ras inhibition on the development of hepatocarcinomas in vivo in adequate animal models.
Ras癌蛋白可能与多种器官的正常和恶性细胞生长有关。抑制Ras会干扰体外和体内非肝细胞的细胞增殖。Ras在正常和恶性肝细胞增殖中的潜在作用促使我们评估FTS(S - 法尼基硫代水杨酸)抑制Ras对人肝癌细胞系HepG2体外肝细胞增殖以及大鼠部分肝切除(PH)后体内肝细胞增殖的影响。大鼠在PH后1、8和16小时腹腔注射FTS,并在PH后12、24和48小时处死。与对照组相比,评估FTS处理大鼠的细胞增殖、MAPK(丝裂原活化蛋白激酶)途径成员的磷酸化以及细胞周期效应物(细胞周期蛋白D、细胞周期蛋白E、细胞周期蛋白依赖性激酶2和细胞周期蛋白依赖性激酶4)的水平和活性。培养7天后,FTS显著降低了HepG2细胞的总体细胞计数、PCNA(增殖细胞核抗原)表达以及BrdU(溴脱氧尿苷)掺入。FTS处理显著降低了PH后肝细胞中BrdU掺入和PCNA表达。与对照大鼠不同,PH后FTS处理的动物中Ras的细胞膜表达降低,导致Raf膜募集和磷酸化减少以及ERK1/2(细胞外信号调节激酶1/2)磷酸化降低。FTS的抗增殖作用与细胞周期蛋白E/细胞周期蛋白依赖性激酶2复合物的表达和活性降低有关,而不影响细胞周期蛋白D和细胞周期蛋白依赖性激酶4。在PH引发强烈且高度同步的增殖刺激后,FTS抑制Ras显著降低了HepG2细胞和正常肝细胞的增殖。这种抑制作用至少部分是由抑制Ras/Raf/MAPK信号传导介导的。在合适的动物模型中评估Ras抑制对体内肝癌发生发展的影响似乎是值得的。